Combined prostate biopsy and laser treatment in one session for urinary symptoms
Tests biopsy and laser treatment together in men with urinary symptoms.
Plain-language title generated from the registry record
Registry title: Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer
Key facts
- Where
- Banhā, EgyptSee the site
Where in Egypt
- Urology Department, Benha University HospitalsBanhā, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Benha University
- Trial code
- NCT07526675
- Record updated
- 30 September 2026
- Original description
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.Read full original descriptionShow less
Validation of Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Symptomatic (LUTS) Selected Most Probably Low and Intermediate Risk PCa Patients
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.
Inclusion: Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:; IPSS score > 20; Uroflowmetry flow rate < 10 ml/sec; Post-void residual > 150 cc; Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:; PSA level between 4 and 20 ng/ml; MP-MRI showing 3 or fewer focal lesions; MP-MRI focal lesions measuring < 1.5 cm; International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination.
Exclusion: Metastatic prostate cancer; History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter); History of pelvic radiation therapy or radical pelvic surgery; Patient PSA level > 20 ng/ml; More than 3 focal lesions on MP-MRI.